| Literature DB >> 35116058 |
Qiyang Shen1, Xingyu Liu2, Wei Li3, Xu Zhao2, Tao Li1, Kai Zhou2, Jianfeng Zhou1.
Abstract
Circular RNAs (circRNAs) are non-coding RNAs with covalent closed-loop structures and are widely distributed in eukaryotes, conserved and stable as well as tissue-specific. Malignant solid tumors pose a serious health risk to children and are one of the leading causes of pediatric mortality. Studies have shown that circRNAs play an important regulatory role in the development of childhood malignant solid tumors, hence are potential biomarkers and therapeutic targets for tumors. This paper reviews the biological characteristics and functions of circRNAs as well as the research progress related to childhood malignant solid tumors.Entities:
Keywords: biological functions; biomarkers; circRNA; epigenetics; pediatric malignant solid tumors
Year: 2022 PMID: 35116058 PMCID: PMC8804321 DOI: 10.3389/fgene.2021.820936
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1CircRNAs are a covalently closed loops formed by splicing of precursor mRNA (pre-mRNAs). There are three forms of circRNAs:lasso-driven cyclization, intron pairing cyclization and RNA binding proteins (RBPs) mediated cyclization. CircRNAs are classified into three main types, exonic circRNAs, intronic circRNAs, and exon-intron circRNAs. (A) CircRNAs can regulate the expression of related genes in cells; (B) CircRNAs as miRNA sponge can adsorb related miRNAs; (C) The functions of circRNA in interacting with proteins; (D) Several circRNAs have also been reported to encode proteins; (E) CircRNAs in exosomes or microvesicles can be used as specific biomarkers; (F) CircRNAs can be degraded via m6A-mediated decay.
Functional characterization of circular RNAs in pediatric malignant soild tumor.
| Circular RNAs | Expression | Role | Function role | miRNAs | Related genes | References |
|---|---|---|---|---|---|---|
| Hepatoblastoma | ||||||
| hsa_circ_0000594 | Upregulated | Oncogene | Promote cell proliferation, invasion, and suppress cell apoptosis | miR-217 | SIRT1 |
|
| circ-STAT3 | Upregulated | Oncogene | Promote cell growth, migration and stem-cell characteristics | miR-29a/b/c-3p | GLI2 |
|
| circ-HMGCS1 | Upregulated | Oncogene | Promote cell proliferation and inhibit cell apoptosis | miR-503-5p | IGF-PI3K-Akt |
|
| Neuroblastoma | ||||||
| circ-CUX1 | Upregulated | Oncogene | Promote aerobic glycolysis, growth, and aggressiveness | - | EWSR1/MAZ |
|
| hsa_circ_0132,817 | Upregulated | Oncogene | Promote cell proliferation, migration, invasion and glycolysis | miR-432-5p | NOL4L |
|
| circ-DGKB | Upregulated | Oncogene | Promote the proliferation, migration, invasion, and tumorigenesis | miR-873 | GLI1 |
|
| circ-CUX1 | Upregulated | Oncogene | Promote tumor progression and glycolysis | miR-338-3p | PHF20 |
|
| circ-KIF2A | Upregulated | Oncogene | Promote cell proliferation, migration, invasion and glycolysis | miR-129-5p | PLK4 |
|
| Circ-CUX1 | Upregulated | Oncogene | Promote cell proliferation, migration, invasion and glycolysis | miR-16-5p | DMRT2 |
|
| Wilms tumors | ||||||
| hsa_circ_0093740 | Upregulated | Oncogene | Promote the growth, migration and metastasis | miR-136/145 | DNMT3A |
|
| circ-CDYL | Upregulated | Oncogene | Promote cell proliferation, migration, and invasion | miR-145-5p | TJP1 |
|
| Rhabdomyosarcoma | ||||||
| circ-ZNF609 | Upregulated | Oncogene | Promote cell cycle | - |
|
|
| circVAMP3 | Upregulated | Oncogene | Promote cell cycle progression | - | AKT-related pathways |
|
| Lymphoma | ||||||
| circ-LAMP1 | Upregulated | Oncogene | Promote cell proliferation and inhibit cell apoptosis | miR-615-5p | DDR2 |
|
| circ-APC | Downregulated | Tumor suppressor | Inhibit cell proliferation and tumor growth | miR-888 | APC and Wnt/β-catenin |
|
| circ-CDYL | Upregulated | Oncogene | Promote cell proliferation | miR-129-5p | NOTCH1 |
|
| miR-3163 | FMR1 | |||||
| miR-4662a-5p | ABCB1 | |||||
| miR-101-3p | TWIST1 | |||||
| miR-186-5p | VEGFA | |||||
| circ-CFL1 | Upregulated | Oncogene | Promote cell proliferation, migration and tumor growth | miR-107 | HMGB1 |
|
| circ-OTUD7A | Upregulated | Oncogene | Promote cell proliferation, metastasis, inhibit cell cycle arrest and apoptosis | miR-431-5p | FOXP1 |
|
| circ-NSUN2 | Upregulated | Oncogene | Promote cell proliferation and invasion | - | HMGA1/Wnt signaling |
|
| Medulloblastoma | ||||||
| circ-SKA3 | Upregulated | Oncogene | Promote cell proliferation, migration, invasion and induced apoptosis and cell cycle arrest | miR-326 | ID3 |
|
| circ-SKA3 and circ-DTL | Upregulated | Oncogene | Promote cell proliferation, migration, and invasion | - | SKA3 and DTL |
|
| circ-SKA3 | Upregulated | Oncogene | Promote cell proliferation, migration, invasion tumor growth and inhibit cell apoptosis | miR-383-5p | FOXM1 |
|
| Adrenocortical Carcinoma | ||||||
| circ-CCAC1 | Upregulated | Oncogene | Promote cell proliferation, migration, and invasion | miR-514a-5p | C22orf46 |
|
The potential of circRNAs in the diagnosis and prognosis of pediatric malignant soild tumor.
| Study | Sample size | circRNAs | Expression | Source | Expression ( | Diagnostic value AUC | Sample size | Prognostic value OS ( | References |
|---|---|---|---|---|---|---|---|---|---|
| Hepatoblastoma | |||||||||
| Zhen et al | (Normal:Tumor) | circ-HMGCS1 | Up | Tissues |
| 0.8283 | Tumor (n = 33) |
|
|
| (37:37) | |||||||||
| Neuroblastoma | |||||||||
| Yang et al | (Normal:Tumor) | circ-DGKB | Up | Blood |
| 0.7778 | Tumor (n = 33) |
|
|
| (10:30) | |||||||||
| Zhang et al | (Normal:Tumor) | circ-CUX1 | Up | Tissues |
| - | Tumor (n = 50) |
|
|
| (50:50) | |||||||||
| Lymphoma | |||||||||
| Mei et al | (Normal:Tumor) | circ-CDYL | Up | Tissues |
| 0.856 | Tumor (n = 18) |
|
|
| (17:18) | |||||||||
| Adrenocortical Carcinoma | |||||||||
| Li et al | (Normal:Tumor) | circ-CCAC1 | Up | Tissues |
| - | Tumor (n = 48) |
|
|
| (48:48) | |||||||||
FIGURE 2The relationships of circRNAs with pediatric malignant solid tumors (A) Signal pathways related to cell proliferation and differentiation; (B) Signaling pathways related to cell cycle regulation; (C) Signaling pathways related to apoptosis; (D) Signal pathways related to tumor cell invasion and metastasis; (E) Signaling pathways related to intracellular oxidative metabolism.